Pipeline
SG-5-00455
Lead Program
- Indication: Inflammatory bowel diseases (IBD)
- Administration: oral, via engineered L. lactis
- Goal: achieve mucosal healing
- Discovered: healthy guts
-
Peptide:
SG-2-0776 -
Target:
PAI-1 / PAI-2 - IP filed
SG-3-06686
Lead Program
- Indication: solid tumors
- Administration: SQ, IV
- Goal: amplify immune signal & induce migration of immune cells to tumor microenvironment
- Discovered: from checkpoint inhibitor responders
-
Peptide:
SG-3-06686
-
Target:
CXCR3
- IP filed
Other
Programs- Indication: oncology and gastrointestinal diseases
8 programs in early discovery
Second Genome therapeutic approach
We are finding novel targets and using the discovered natural peptides to drug what historically has been undruggable targets
Our approach: microbial secretion
Microbes release peptides to influence their human host via specific human targets. Second Genome approach is to identify these peptide-human target interactions and then utilize the peptide to develop a therapeutic agent.